The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: The South African Not at Goal study (SA-NAG)

Cardiovascular Journal of Africa

Volumn 19, Issue 2, 2008, Pages 88-94

  Ramjeeth, Akash ^a   Butkow, Neil ^a   Raal, Frederick ^a   Maholwana Mokgatlhe, Mandisa ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRACTICE GUIDELINE; SOUTH AFRICA;

AGE DISTRIBUTION; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPERLIPIDEMIAS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 45349090253     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cholesterol Treatment Trialist's (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2003; 360: 7-22.
3. Nissen SE, Tuzcu EM, Schoenhagen P, Vogel RA, Brown BG, Ganz P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2004; 291: 1071-1080.
4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
6. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. J Am Med Assoc 2006; 295: 1556-1565.
7. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-2864.
8. Amira C, Ntyintyane L, Wilkinson D, Stewart S, Becker A, Libhaber E, et al. Emerging epidemic of cardiovascular disease among urban Africans: Acute coronary syndrome at Baragwanath Hospital, Soweto. S Afr Heart J 2006; 3: 7-12.
9. Kadiri S. Tackling cardiovascular disease in Africa. Br Med J 2005; 331: 711-712.
10. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26: 2224-2231.
11. South African Medical Association and Lipid and Atherosclerosis society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa - clinical guideline, 2000. S Afr Med J 2000; 90: 164-178.
12. Raal FJ, Schamroth C, Klug E, Mills P. Editorial. South African lipid guidelines: Is there a need for an update? Cardiovasc J South Afr 2004; 15: 53-54.
13. Raal FJ, Marais AD, Schamroth C. A statement from the Lipid and Atherosclerosis Society of Southern Africa (LASSA) in conjunction with the South African Heart Association (SA Heart): Adoption of the European guidelines on cardiovascular disease prevention in clinical practice - guide to lipid management. S Afr Heart J 2006; 3: Insert (July - winter edition).
14. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
15. Expert Panel on detection, evaluation, and treatment of high cholesterol in adults. Executive summary of the third report of the National Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: e285-290; 2735-2752.
17. Grundy SM, Cleeman JI, Merz NB, Brewer B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
18. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-640.
19. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A Multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
20. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol 2005; 96: 556-563.
21. Böhler S, Scharnagel H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, et al. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 2007; 190: 397-407.
22. Diamantopoulos EJ, Athyros VJ, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology 2005; 56: 731-741.
23. Banegas JR, Vegazo O, Serrano P, Luengo E, Mantilla T, Fernández R, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 2006; 188: 420-424.
24. Erhardt L, Pearson TA, Bruckert E, Leiter LA, Conroy RM, Hobbs FDR, et al. Guidelines and their implementation: A discussion document focused on the best approaches to drive improvement. Vasc Dis Prev 2004; 1: 167-174.
25. Graham IM, Stewart M, Hertog, on behalf of the Cardiovascular Round Table Task Force. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006; 13: 839-845.
26. Steyn K, Fourie JM, Shepherd J. Detection and measurement of hypercholesterolaemia in South Africans attending general practitioners in private practice - the Cholesterol Monitor. S Afr Med J 1998; 88:1569-1574.
27. Alberts M, Urdal P, Steyn K, Stensvold I, Tverdal A, Nel JH, et al. Prevalence of cardiovascular diseases and associated risk factors in a rural black population of South Africa. Eur J Cardiovasc Prev Rehabil 2005; 12: 347-354.
28. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
30. Erhardt L, Pearson TA, Bruckert E, Leiter LA, Conroy RM, Hobbs FDR, et al. Guidelines and their implementation: A discussion document focused on the best approaches to drive improvement. Vasc Dis Prev 2004; 1: 167-174.
31. Zagrosek VR. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Disc 2006; 5: 425-438.
32. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111: 499-510.
33. Bradshaw D. Editorial. What do we know about the burden of cardiovascular disease in South Africa? Cardiovasc J South Afr 2005; 16: 140-141.
34. De Backer G, Ambrosio GB, Amouyel P, Cokkinos D, Deckers J, Erhardt L, et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II: Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
35. Pearson TA, Denke MA, Mcbride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-595.
36. Ballantyne CM, Sosef F, Duffield E. Rosuvastatin plus ezetimibe for achievement of low-density lipoprotein cholesterol and C-reactive protein goals: results from the EXPLORER study. World Congress of Cardiology. Barcelona, Spain, September 2006. (abstract 5390).
37. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study (TNT). Lancet 2006; 368: 919-928.
38. Larsson B. Obesity and body fat distribution as predictors of coronary heart disease. In: Marmot M, Elliott P, eds. Coronary Heart Disease Epidemiology. From Aetiology to Public Health. Oxford: Oxford University Press, 1992: 233-241.
39. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentration and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185-2189.